Aroda VR, Capehorn MS, Chaykin L, et al. - In patients with type 2 diabetes (T2D), researchers assessed the effect of relevant patient-level features on the effectiveness and safety of subcutaneous, once-weekly semaglutide. Exploratory post hoc analyses of pooled SUSTAIN 1–5 (phase 3a) randomized, controlled trials studied the change from baseline in HbA1c and body weight (BW), and the proportions of individuals reaching the composite endpoint (HbA1c <7.0% [53 mmol/mol], without weight gain or severe/blood glucose-confirmed symptomatic hypoglycaemia) at week 30 with semaglutide (0.5/1.0 mg) across clinically relevant patient subgroups: baseline HbA1c (≤ 7.5, > 7.5–8.0, > 8.0–8.5, > 8.5–9.0 and > 9.0%), background medications, diabetes duration and pancreatic beta-cell function. Investigators found that reductions of HbA1c and BW were consistently higher for semaglutide 1.0 mg vs 0.5 mg across background medication, diabetes duration and pancreatic beta-cell function subgroups. In a broad spectrum of patient subgroups with a range of clinical features, semaglutide was consistently efficacious across the continuum of diabetes care. Semaglutide adverse events were consistent with the GLP-1RA class, with most common gastrointestinal events.